Pharmacokinetics of phenylbutazone in neonatal foals.

The research article discusses a study on how a drug called phenylbutazone, administered to newborn foals (baby horses), is processed within their bodies. The study found differences in the way these foals process the drug compared to adult horses.

Study Setup

• The research involved administering single doses (2.2 mg/kg of body weight) of phenylbutazone to six neonatal horses that were between 5 to 17 hours old at the time of dosing.
• Phenylbutazone and its metabolite oxyphenbutazone in plasma were monitored over a period of 120 hours after giving them the drug.
• The pharmacokinetic variables, which determine how the drug is processed in the body, were calculated using mathematical models known as 1- and 2-compartment open models.

Key Findings

• The median volume of distribution at steady state was reported as 0.274 L/kg. The volume of distribution, which reflects the amount of drug in the body relative to the concentration of the drug in the blood, ranged between 0.190 and 0.401 L/kg for the tested foals.
• The median terminal half-life, which is the time required for the concentration of the drug to reach half of its original value, was found to be 7.4 hours (ranging between 6.4 and 22.1 hours).
• The total plasma clearance of phenylbutazone, which is a measure of the body’s efficiency in removing the drug, came out as 0.018 L/kg/h (ranging from 0.013 to 0.038 L/kg/h).
• When compared to similar studies on adult horses, it was found that the volume of distribution was larger, the half-life was longer, and the total clearance was lower in newborn horses.

Implications of the Research

• This research informs us about how a specific drug is processed by the body of newborn horses, which could help in understanding and managing the use of this drug in treating horses.
• These differences in pharmacokinetic variables between adult horses and foals might require adjustments in drug dosing to achieve therapeutic effectiveness while avoiding toxicity.